Newly published work in Neuro-Oncology spotlights a molecular vulnerability in glioblastoma (GBM), the most aggressive primary brain tumor. The study,...

Multiple myeloma (MM) treatment is entering a “de-escalation” era: clinicians aim to preserve deep, durable disease control while lowering long-term...

Insilico Medicine has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ISM6331, an...

Hospitals are not only places where childhood cancer is treated—they also generate records of earlier health encounters. A new population-based...

Mitochondria have long been treated as cellular powerhouses, but a new study reframes them as potential vehicles for targeted cancer...

A new analysis published in British Journal of Cancer maps how oncology drug development in the UK has evolved over...

A new Nature Communications study reports a high-resolution immune atlas of natural killer/T-cell lymphoma using single-cell profiling, offering a clearer...

Gastrointestinal cancers still claim a disproportionate share of global cancer burden—about one fifth of all cases and roughly one third...

A new study in Cell Death Discovery reports that a microRNA known as miR-195-5p can steer the molecular fate of...

Insilico Medicine has announced that first-in-human Phase 1 data for ISM6331, an AI-designed pan-TEAD inhibitor, has been accepted for a...